“The purpose of the experiments was to explore the role of the endocannabinoid system, through cannabinoid (CB) receptor ligands, nicotine and scopolamine, in the depression-related responses using the forced swimming test (FST) in mice…
Our results provide clear evidence that the endocannabinoid system participates in the depression-related behavior and through interactions with cholinergic system modulate these kind of responses.”
“Cannabis has been demonstrated to have bronchodilator, anti-inflammatory and anti-tussive activity in the airways, but, information on the active cannabinoids, their receptors and the mechanisms for their effects is limited.
We compared the effects of Δ9-tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene, cannabidiolic acid and tetrahydrocannabivarin…
The other cannabinoids did not influence cholinergic transmission and only Δ9-THC demonstrated effects on airway hyperresponsiveness, anti-inflammatory activity and antitussive activity in the airways.”
http://www.ncbi.nlm.nih.gov/pubmed/25655949
http://jpet.aspetjournals.org/content/early/2015/02/05/jpet.114.221283.long
“Cannabinoid Δ9-tetrahydrocannabinol (THC) is effective in treating osteoarthritis (OA)…
Activation of cannabinoid receptor CB2 reduces inflammation; whether the activation CB2 is involved in THC-induced therapeutic action for OA is still unknown.
We hypothesized that the activation of CB2 is involved in THC-induced anti-inflammation in the MG-63 cells exposed to LPS, and the anti-inflammation is mediated by cofilin-1…
We found that THC suppressed the release of proinflammatory factors, including tumor necrosis factor α (TNF-α), interleukin- (IL-) 1β, IL-6, and IL-8, decreased nuclear factor-κB (NF-κB) expression, and inhibited the upregulation of cofilin-1 protein in the LPS-stimulated MG-63 cells.
These results suggested that CB2 is involved in the THC-induced anti-inflammation in LPS-stimulated MG-63 cells, and the anti-inflammation may be mediated by cofilin-1.”
http://www.ncbi.nlm.nih.gov/pubmed/25653478
“Germinal matrix hemorrhage (GMH) is one of the most common and devastating cerebrovascular events that affect premature infants, resulting in a significant socioeconomic burden. However, GMH has been largely unpreventable, and clinical treatments are mostly inadequate.
In the present study, we tested the hypothesis that a selective CB2 receptor agonist, could attenuate brain injury and neurological deficits…
This current study suggests a potential clinical utility for CB2R agonists as a potential therapy to reduce neurological injury and improve patient outcomes after GMH.”
CB1R was involved in the nerve growth of ectopic cyst associated with endometriosis.”
“… a systematic review to assess the effectiveness of cannabis extracts and cannabinoids in the management of chronic nonmalignant neuropathic pain…
Randomized placebo-controlled trials (RCTs) involving cannabis and cannabinoids for the treatment of chronic nonmalignant pain were selected…
Evaluation of these studies suggested that cannabinoids may provide effective analgesia in chronic neuropathic pain conditions that are refractory to other treatments.
Conclusion: Cannabis based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments. ”
http://www.ncbi.nlm.nih.gov/pubmed/25635955
http://www.thctotalhealthcare.com/category/neuropathic-pain/
“Pro-inflammatory cytokines, growth and angiogenic factors released by leukocytes are involved in carcinogenesis and cancer progression, but they are also crucial for fighting tumour growth and spreading.
We have previously demonstrated that endocannabinoids modulate cell-to-cell crosstalk during inflammation. Here, we investigated the inflammatory and tumourigenic properties of endocannabinoids in a human urinary bladdercarcinoma cell line…
Collectively, these findings suggest that CB receptors may play distinct roles in cancer biology, depending on the specific ligand employed.
The in vivo assessment of the role of CB receptors in inflammation and cancer might be instrumental in broadening the understanding about bladder cancer biology.”
“To investigate the association of cannabis use and tobacco smoking on the incidence of bladder cancer within the California Men’s Health Study cohort…
…using tobacco only was associated with an increased risk of bladder cancer, whereas cannabis use only was associated with a 45% reduction in bladder cancer incidence.
Although a cause and effect relationship has not been established, cannabis use may be inversely associated with bladder cancer risk in this population.”
“Cannabinoids exert antitumorigenic effects via multiple mechanisms.
Of these, antimetastatic and antiangiogenic actions have attracted considerable interest in the past years…
This chapter reviews the cell- and substance-specific antitumorigenic mechanisms of cannabinoids with particular consideration of their antimetastatic/anti-invasive and antiangiogenic actions.
In addition, beneficial interactions of cannabinoids with currently used chemotherapeutics as well as the influence of cannabinoids on tumor-immune surveillance are addressed.
Collectively, the currently available data suggest cannabinoids as a potential tool in modern cancer pharmacotherapy.”
“Preclinical and clinical data suggest that cannabidiol (CBD), a major non-psychotomimetic compound from Cannabis sativa, induces antipsychotic-like effects…
These results indicate that repeated treatment with CBD, similar to clozapine, reverses the psychotomimetic-like effects and attenuates molecular changes observed after chronic administration of an NMDAR antagonist.
These data support the view that CBD may have antipsychotic properties.” http://www.ncbi.nlm.nih.gov/pubmed/25618402
“Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug… a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia.” http://www.ncbi.nlm.nih.gov/pubmed/16612464
“A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation… These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.” http://www.ncbi.nlm.nih.gov/pubmed/22716160